Health & Biotech
ASX Health Stocks: Upcoming clinical trials for these two ASX-listed neuro disease biotechs
Health & Biotech
ASX Health Stocks: Lumos down 65pc on FDA rejection; and is Hexima belly-up after Phase 2 readout?
Health & Biotech
ASX Health Stocks: MXC tests positive in South Africa for COVID-19; NTI high on cannabis v autism in kids
Health & Biotech
Neurotech study says cannabis could be key to helping kids on the spectrum reach potential
Health & Biotech
ASX Health Stocks: FDA to expedite submission for Botanix’s sweaty armpits gel
Health & Biotech
Check Up: These biotech themes got billions in VC funding. These ASX stocks could benefit
Health & Biotech
ASX Health Stocks: ResApp gets FDA nod, while Japan grants Immutep a patent
Health & Biotech
ASX Health Stocks: US patent another Prescient win for booming Aussie biotechs
Health & Biotech
Dimerix latest study offers hope for chronic obstructive pulmonary disease
Health & Biotech
ASX Health Stocks: HitIQ and Volpara prove world class technology after signing major US deals
Health & Biotech
EZZ’s cashes in on China’s multi-billion dollar e-commerce shopping festival with one product proving a winner
Health & Biotech
Dr Boreham’s Crucible: Will the FDA bend the knee after Paradigm’s Phase III tests?
Featured Health & Biotech Stocks
Health & Biotech
Healthcare stocks are as varied as the solutions they are working to solve. The sector covers biotech stocks developing breakthrough pharmaceutical drugs and vaccines to medtech companies launching the latest and greatest medical devices they hope will change the face of healthcare.
Even the ‘budding’ medical cannabis industry is in the mix as researchers explore new applications and treatments.
If you want to know what’s happening with emerging health stocks on the ASX, Stockhead has you covered, with daily stock news, expert insight and research. You can also recap broader industry trends and recent share price movements across the sector in our regular ‘Check Up’ feature.
Accurate, up-to-date news stories are important, especially in the health sector where progress is often slow and risk often high. That’s why we’re focused on helping small cap investors make sense of the medical jargon.